Placental Malaria Immunology and Glycosaminoglycan Interactions

Placental malaria arises when Plasmodium falciparum–infected erythrocytes accumulate in the placental intervillous space by binding to chondroitin sulfate A, a glycosaminoglycan on the syncytiotrophoblast. This sequestration provokes a local inflammatory response, impairs nutrient and oxygen transfer and drives maternal anaemia, foetal growth restriction and adverse birth outcomes. Protective immunity develops over successive pregnancies as women acquire antibodies that block infected erythrocyte adhesion, promote opsonophagocytosis and activate complement. At the same time, the parasite evolves evasion strategies, including binding to host immunoglobulin M to subvert complement activation and exploiting shear forces to increase adhesion avidity. Recent advances in structural biology have delineated the modular architecture of VAR2CSA and its cryptic glycan-binding sites, guiding immunogen design for vaccine development and informing serosurveillance strategies. Understanding the interplay between antibody-mediated protection and parasite escape mechanisms is critical for developing broadly effective interventions against pregnancy-associated malaria.

Research from Nature Portfolio

High-resolution cryo-electron microscopy has revealed how several VAR2CSA and related parasite proteins bind human immunoglobulin M in distinct modes. These interactions directly inhibit IgM-mediated complement activation, with VAR2CSA showing the strongest effect in functional assays. The structural insights demonstrate that VAR2CSA not only mediates placental sequestration via glycosaminoglycan recognition but also serves as a potent immune evasion factor by dampening the early humoral response. This dual functionality highlights new molecular targets for therapeutic interruption of both adhesion and complement evasion.

Placental Malaria Immunology and Glycosaminoglycan Interactions publication trend

The graph below shows the total number of articles in placental malaria immunology and glycosaminoglycan interactions across all publications each year (not limited to Nature Index journals).

Technical terms

VAR2CSA: A large, multidomain Plasmodium falciparum erythrocyte membrane protein that binds chondroitin sulfate A in the placenta, mediating infected erythrocyte sequestration.

Glycosaminoglycan (GAG): A family of long, linear polysaccharides (e.g. chondroitin sulfate A) attached to proteoglycans in the placental extracellular matrix, serving as receptors for parasite adhesion.

Chondroitin Sulfate A (CSA): A sulphated glycosaminoglycan on syndecan-1 proteoglycans of the syncytiotrophoblast surface targeted by VAR2CSA.

Immunoglobulin M (IgM): The first antibody isotype produced during an immune response, capable of activating the classical complement pathway.

Complement activation: A cascade of serum proteins that enhances pathogen opsonisation, formation of membrane attack complexes and clearance of infected cells; can be inhibited by parasite proteins binding to IgM.

References

1. Plasmodium falciparum has evolved multiple mechanisms to hijack human immunoglobulin M. Nature Communications (2023).
2. Acquisition of antibodies that block Plasmodium falciparum adhesion to placental receptor chondroitin sulfate A with increasing gravidity in Malian women. Frontiers in Immunology (2024).
3. Structure-guided design of VAR2CSA-based immunogens and a cocktail strategy for a placental malaria vaccine. PLOS Pathogens (2024).
4. Mechanical forces control the valency of the malaria adhesin VAR2CSA by exposing cryptic glycan binding sites. PLOS Computational Biology (2023).
5. Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1. PLOS Pathogens (2016).